|
| |
|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Dec 29 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Shionogi Takes Full Control of Radicava in $2.5B Buyout Move
|
|
| | AstraZeneca Bets Big on KRAS with $2B Jacobio Alliance
|
|
| | Ipsen Secures Global Oncology Asset in $1.06B Simcere Zaiming Deal
|
|
| | Windward Bio Locks In $700M Dual-Target Asthma Bet
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Mega-Cap Biopharma: Christmas Week Highlights
|
| |
|
| |
Pfizer
|
| |
Quiet Holidays, Active Pipelines
Pfizer closed the year reinforcing its oncology and vaccine strategy, advancing late-stage readouts and preparing regulatory filings that will shape its 2026 growth outlook.
|
| |
Roche
|
| |
Diagnostics + Oncology at the Core
Roche entered the holiday season with continued momentum in oncology and diagnostics, underscoring its integrated approach to precision medicine as regulatory wins stack up.
|
| |
Novartis
|
| |
Portfolio Sharpening Pays Off
Novartis wrapped up the year focused on high-value innovative medicines, with pipeline execution and capital discipline reinforcing confidence in its long-term growth engine.
|
| |
Merck & Co. (MSD)
|
| |
Immuno-Oncology Momentum Holds
Merck sustained strong end-of-year visibility across its oncology franchise, with lifecycle management and late-stage assets keeping its growth narrative intact.
|
| |
Johnson & Johnson
|
| |
Focused Pharma, Strong Finish
With its pure-play pharma strategy now firmly in place, J&J ended the year advancing immunology and oncology programs while maintaining regulatory momentum globally.
|
| |
Sanofi
|
| |
Rebuilding Through Innovation
Sanofi used the year-end window to reinforce its immunology and vaccine roadmap, signaling continued portfolio renewal heading into the new year.
|
| |
AstraZeneca
|
| |
Execution at Scale
AstraZeneca closed the year with sustained clinical and commercial execution, particularly across oncology and rare diseases, reinforcing its multi-year growth trajectory.
|
| |
GSK
|
| |
Vaccines Drive Confidence
GSK entered the holidays with strong vaccine franchise momentum, supported by steady R&D execution across respiratory and infectious diseases.
|
| |
The Big Picture
|
| |
Christmas may slow the calendar—but not mega-cap biopharma.
Behind the scenes, pipelines advanced, approvals landed, and 2026 strategies took shape.
|
| |
|
| |
| | $2.5B Radicava Buyout: Shionogi Doubles Down on Neurodegenerative Leadership
|
|
|
|
|
| |
Shionogi Acquires Full Rights to Radicava Franchise in $2.5B Deal
|
| |
|
| |
Shionogi has announced a definitive agreement to acquire a newly established company to be created by Tanabe Pharma, which will hold all rights to Radicava ORS (edaravone) and IV Radicava.
|
| |
Why This Acquisition Matters
|
| |
| • | High-value transaction: Shionogi will pay $2.5 billion upfront, with future royalties payable to Tanabe Pharma based on defined commercial milestones.
|
|
| • | Streamlined global operations: Tanabe will spin out a new entity holding Radicava assets, which Shionogi will acquire in full—making Tanabe’s U.S. Radicava business a wholly owned subsidiary of Shionogi.
|
|
| • | Established growth platform: The Radicava portfolio includes both oral and IV formulations of edaravone, approved for amyotrophic lateral sclerosis (ALS) and supported by global commercialization infrastructure.
|
|
| • | Strategic portfolio expansion: The acquisition secures Shionogi’s long-term control over the Radicava brand, enhancing synergies across clinical innovation, regulatory oversight, and market access.
|
|
| • | Focused therapeutic continuity: Retaining Radicava’s experienced teams ensures operational and patient-care consistency during integration.
|
|
| |
A Strategic Step Forward
|
| |
For Shionogi, the acquisition represents a decisive move to build scale and continuity in neurodegenerative care, consolidating one of Japan’s most globally recognized neurology assets. The transaction enables unified stewardship of the Radicava brand, supporting continued research into edaravone’s broader potential beyond ALS. By bringing development, manufacturing, and commercialization under one roof, Shionogi is positioning itself for sustained leadership in therapies that improve outcomes for patients with devastating neurological conditions.
|
| |
|
| |
| | Science, Capital, and Collaboration: The Deals Advancing Care
|
|
|
|
|
| |
|
| |
Jacobio and AstraZeneca Forge $2B KRAS Licensing Alliance
|
| |
Advancing Next-Generation Oncology Through Global Collaboration
|
| |
Jacobio Pharma has entered into a global exclusive licensing agreement with AstraZeneca for JAB-23E73, a pan-KRAS inhibitor targeting multiple KRAS mutation subtypes. Under the agreement, AstraZeneca obtains exclusive rights to develop and commercialize the therapy outside China, while both companies will collaborate on joint development and commercialization within China.
|
| |
Why This Partnership Matters
|
| |
| • | High-value agreement: Jacobio will receive an upfront payment of $100 million and is eligible for up to $1.91 billion in milestones, along with tiered royalties on net sales outside China.
|
|
| • | Collaborative structure: AstraZeneca will lead clinical development, regulatory activities, and global commercialization beyond China, ensuring efficient global execution.
|
|
| • | Innovative pipeline asset: JAB-23E73, a pan-KRAS inhibitor, is designed to target multiple KRAS mutation subtypes—offering potential treatment across a broad spectrum of KRAS-driven cancers.
|
|
| • | Clinical progress: The candidate is currently being evaluated in Phase I studies in China and the U.S., showing early anti-tumor activity in patients with KRAS-mutated tumors.
|
|
| • | Strategic oncology focus: The alliance aligns with AstraZeneca’s strategy to build leadership in next-generation small molecules and targeted cancer therapies.
|
|
| |
A Strategic Step Forward
|
| |
For AstraZeneca, the partnership reinforces its commitment to advancing breakthrough science in oncogenic RAS inhibition, a frontier long considered undruggable. For Jacobio, the deal provides global scale, capital support, and collaboration with one of the foremost leaders in oncology innovation. Together, the companies are positioned to accelerate the development of JAB-23E73—potentially shaping a new era in the treatment of KRAS-mutated cancers worldwide.
|
| |
Ipsen Inks $1.06B Global Oncology Licensing Deal with Simcere Zaiming
|
| |
Expanding Access to Next-Generation Cancer Therapies Beyond Greater China
|
| |
Ipsen has entered into an exclusive global licensing agreement with Simcere Zaiming for SIM0613, a novel oncology asset targeting hard-to-treat solid tumors with high unmet medical need. The collaboration grants Ipsen global development and commercialization rights outside Greater China, while consolidating its commitment to sourcing first-in-class innovation from emerging biopharma leaders in Asia.
|
| |
Why This Partnership Matters
|
| |
| • | High-value agreement: The deal is valued at up to $1.06 billion, including upfront, development, regulatory, and commercial milestone payments, plus tiered royalties on future sales.
|
|
| • | Global development rights: Ipsen gains exclusive rights outside Greater China and will lead all clinical development and regulatory submissions beginning with Phase I preparation and IND/CTA filings.
|
|
| • | Technology transfer and manufacturing: The agreement includes manufacturing rights for Ipsen following technology transfer, ensuring scalable production capabilities for global markets.
|
|
| • | Strategic oncology expansion: SIM0613 strengthens Ipsen’s oncology portfolio, aligning with its focus on delivering transformative therapies across solid tumor indications.
|
|
| • | Cross-border innovation: The collaboration exemplifies ongoing momentum in China-originated drug innovation, bridging local discovery with global clinical and commercial execution.
|
|
| |
A Strategic Step Forward
|
| |
For Ipsen, the partnership underscores its ambition to diversify and globalize its oncology pipeline, integrating external innovation with its development and commercialization expertise. For Simcere Zaiming, it reflects the company’s evolution into a globally recognized R&D partner, bringing its cutting-edge oncology programs to a worldwide audience. Together, the two companies are poised to accelerate the development of SIM0613, potentially offering new hope for patients with aggressive solid tumors that currently lack effective treatment options.
|
| |
Windward Bio Inks $700M Global Licensing Deal for Dual-Target Asthma Therapy
|
| |
Advancing Dual-Pathway Biologics in Respiratory Disease
|
| |
Windward Bio, through its affiliate LE2025 Therapeutics, has entered into a global licensing agreement with Qyuns to develop and commercialize WIN027 (QX027N), a bispecific antibody designed to simultaneously target TSLP and IL‑13. The collaboration strengthens Windward’s leadership in next-generation respiratory biologics, expanding its therapeutic footprint across asthma and COPD.
|
| |
Why This Partnership Matters
|
| |
| • | High-value licensing deal: The agreement is valued at approximately $700 million, comprising an upfront payment, equity stake, and development, regulatory, and commercial milestones, plus tiered royalties on future sales.
|
|
| • | Exclusive global rights: Windward obtains exclusive rights to develop, manufacture, and commercialize WIN027 outside China, while Qyuns retains rights within China.
|
|
| • | Innovative dual-target mechanism: WIN027 targets both TSLP and IL‑13, two key cytokines implicated in type 2 inflammation, aiming to deliver broader and more durable efficacy than single-target biologics.
|
|
| • | Pipeline synergy: The agreement complements Windward’s existing respiratory portfolio, led by WIN378 (anti‑TSLP mAb), currently in the global Phase II POLARIS trial for asthma, with initial data expected in 2026 and a Phase II COPD trial planned the same year.
|
|
| • | Strategic expansion: The partnership enhances Windward’s access to innovative biologics platforms and strengthens its position in upper-tier respiratory research and commercialization.
|
|
| |
A Strategic Step Forward
|
| |
For Windward Bio, this deal marks a bold step toward building a global respiratory leadership franchise, integrating advanced antibody engineering with a focus on multi-pathway modulation. For Qyuns, the collaboration provides a global launch opportunity for its bispecific innovation and access to Windward’s clinical and commercial capabilities. Together, the companies are advancing a next-generation approach to asthma and COPD therapy, combining scientific innovation with global scalability to achieve better outcomes for patients with severe respiratory disease.
|
| |
Rectify and Boehringer Ingelheim Join Forces to Target Pathologic Calcification in CKD
|
| |
Advancing Mechanism-Driven Oral Therapies for Rare and Chronic Diseases
|
| |
Rectify Pharma has announced a strategic research and licensing collaboration with Boehringer Ingelheim (BI) to accelerate the discovery and development of oral small‑molecule therapies for chronic kidney disease (CKD) and related conditions. The collaboration combines Rectify’s Positive Functional Modulators (PFM) platform with BI’s development expertise to restore or enhance ABCC6 function, targeting pathologic calcification—a fundamental driver of disease progression in CKD, pseudoxanthoma elasticum (PXE), and generalized arterial calcification of infancy (GACI).
|
| |
Why This Collaboration Matters
|
| |
| • | High‑value framework: Rectify will receive an upfront payment and is eligible for up to $448 million in preclinical, clinical, regulatory, and commercial milestones, plus tiered royalties on future sales.
|
|
| • | Mechanistic innovation: The collaboration focuses on ABCC6 modulation to address pathologic calcification at its source, rather than managing downstream symptoms.
|
|
| • | Platform synergy: Rectify’s PFM platform enables discovery of small molecules that restore transporter function, offering a blueprint for disease‑modifying oral therapies.
|
|
| • | Broad therapeutic scope: The partnership extends beyond CKD to include rare calcification disorders such as PXE and GACI, highlighting potential for cross‑indication impact.
|
|
| • | Strategic alignment: The alliance fits BI’s mission to advance mechanism‑based approaches for renal and fibrotic diseases, expanding its scope across early‑stage innovation partnerships.
|
|
| |
A Strategic Step Forward
|
| |
For Rectify, the collaboration validates its PFM platform as a transformative modality to correct underlying protein dysfunction in chronic and rare diseases. For Boehringer Ingelheim, it reinforces a strategy to pursue mechanistic, small‑molecule solutions that can halt or reverse disease progression in kidney and calcification disorders. Together, the partners aim to pioneer the first oral, disease‑modifying therapies directed at pathologic calcification, potentially reshaping treatment paradigms for millions of patients affected by CKD and other progressive conditions.
|
| |
Italfarmaco and JCR Establish Exclusive Japan Licensing Deal for Duvyzat
|
| |
Expanding Access to Duchenne Muscular Dystrophy Therapies in Asia
|
| |
Italfarmaco has entered into an exclusive licensing agreement with JCR Pharmaceuticals for the development and commercialization of givinostat—marketed as Duvyzat in the U.S., EU, and UK—in Japan. The collaboration expands the global reach of this novel histone deacetylase (HDAC) inhibitor for Duchenne muscular dystrophy (DMD), a rare genetic muscle disorder with significant unmet need.
|
| |
Why This Partnership Matters
|
| |
| • | Exclusive Japan rights: JCR obtains exclusive commercialization rights to givinostat (Duvyzat) in Japan and will lead clinical development and regulatory filing activities locally.
|
|
| • | Marketed innovation: Duvyzat is the first and only non‑steroidal therapy approved to slow disease progression in DMD, providing an important new treatment option for patients and caregivers.
|
|
| • | Strategic expansion: The partnership enhances Italfarmaco’s international footprint while allowing JCR to leverage its expertise in Japan’s rare disease landscape.
|
|
| • | Broader collaboration potential: Beyond givinostat, the agreement establishes a framework for future R&D partnerships, enabling joint exploration across JCR’s pipeline and platform technologies.
|
|
| • | Accelerated access: The alliance is designed to expedite the availability of Duvyzat for Japanese patients through localized development and early regulatory engagement.
|
|
| |
A Strategic Step Forward
|
| |
For Italfarmaco, this partnership extends its DMD franchise into one of the world’s largest rare disease markets, reinforcing its commitment to global patient access and clinical innovation. For JCR Pharmaceuticals, it adds a key commercial-stage asset aligned with its mission to address rare genetic disorders through scientific excellence and local expertise. Together, the companies are poised to advance treatment availability for DMD and explore broader collaborations that could deliver transformative therapies to patients with high unmet medical need across Japan and beyond.
|
| |
|
| |
Zydus Strengthens U.S. Biosimilar Presence with FDA-Approved Lucentis Alternative
|
| |
Advancing Affordable Access in Ophthalmic Biologics
|
| |
Zydus Lifesciences has entered into a strategic licensing, supply, and commercialization agreement with Bioeq AG for Nufymco (ranibizumab)—an FDA‑approved, interchangeable biosimilar to Lucentis (ranibizumab). The collaboration bolsters Zydus’s biosimilar portfolio in ophthalmology, expanding its reach in the high‑value U.S. retinal therapy market.
|
| |
Why This Partnership Matters
|
| |
| • | Regulatory milestone: Nufymco received BLA approval from the U.S. FDA on December 18, 2025, clearing the path for commercial launch in the U.S.
|
|
| • | Collaborative framework: Bioeq will manage development, manufacturing, regulatory compliance, and product supply, while Zydus will lead commercialization and market access efforts in the U.S.
|
|
| • | Interchangeability designation: As an interchangeable biosimilar to Lucentis, Nufymco can be substituted at the pharmacy level, enhancing adoption potential and patient access.
|
|
| • | Portfolio expansion: The deal strengthens Zydus’s U.S. biosimilars presence, particularly in ophthalmology, complementing its pipeline focused on biologics for chronic and specialty conditions.
|
|
| • | Market opportunity: Entry into the retinal biologics segment positions Zydus among key players addressing wet AMD, diabetic macular edema, and related indications with cost‑effective alternatives.
|
|
| |
A Strategic Step Forward
|
| |
For Zydus Lifesciences, this agreement represents a significant advance in its U.S. biologics growth strategy, aligning with its goal to make high‑quality, affordable therapies accessible to patients. For Bioeq, it ensures commercial scale‑up with a trusted partner experienced in biosimilar distribution and market integration. Together, the companies are poised to expand access to retinal treatments through a launch‑ready, interchangeable biosimilar that supports both affordability and innovation in ophthalmic care.
|
| |
|
| |
Samsung Biologics Expands into the U.S. with $280M Acquisition of Human Genome Sciences Facility
|
| |
Establishing a Strategic Manufacturing Foothold in North America
|
| |
Samsung Biologics has entered into a definitive agreement through its U.S. subsidiary to acquire 100% of Human Genome Sciences from GSK, marking the company’s first U.S.-based manufacturing footprint in Rockville, Maryland. The move reinforces Samsung Biologics’ long-term vision of global diversification and expanded access to key biopharma partners in the North American market.
|
| |
Why This Acquisition Matters
|
| |
| • | High-value transaction: Samsung Biologics will acquire the Rockville manufacturing assets for $280 million, with the transaction expected to close by the end of Q1 2026.
|
|
| • | Operational continuity: More than 500 employees will be retained, ensuring seamless operations and preserving deep biologics manufacturing expertise.
|
|
| • | Robust infrastructure: The cGMP site comprises two manufacturing plants with a combined 60,000 L of drug substance capacity, supporting both clinical and commercial production.
|
|
| • | Strategic U.S. presence: The acquisition grants Samsung a critical manufacturing base in the United States, enhancing customer proximity and responsiveness to regional demand.
|
|
| • | Future growth: Samsung plans additional investments to modernize and expand capacity, advancing next-generation biologics manufacturing technologies.
|
|
| |
A Strategic Step Forward
|
| |
For Samsung Biologics, this acquisition marks a pivotal step in its mission to become a global leader in end-to-end biologics manufacturing, extending its presence from Asia to the U.S. and Europe. The deal positions Samsung to deliver faster, more flexible production support for North American biopharma clients. By integrating the Rockville site and workforce, Samsung aims to expand capacity, strengthen supply reliability, and accelerate the delivery of advanced therapeutics worldwide.
|
| |
Gilead Strengthens Precision Oncology with $30M Acquisition of Repare’s Polθ Inhibitor
|
| |
Expanding Capabilities in DNA Damage Response Therapeutics
|
| |
Gilead Sciences has entered into a definitive asset purchase agreement with Repare Therapeutics to acquire RP‑3467, a polymerase theta (Polθ) ATPase inhibitor, further advancing Gilead’s precision oncology pipeline. The acquisition underscores Gilead’s increasing investment in DNA damage response (DDR) mechanisms—an area of strategic focus for next‑generation targeted cancer therapeutics.
|
| |
Why This Acquisition Matters
|
| |
| • | Targeted oncology transaction: The deal is valued at up to $30 million, comprising a $25 million upfront payment (subject to customary adjustments) and an additional $5 million tied to completion of specified technology transfer activities.
|
|
| • | Novel mechanism of action: RP‑3467 inhibits polymerase theta (Polθ), a key DNA repair enzyme involved in microhomology‑mediated end joining, offering a synthetic lethality approach in tumors with DNA repair deficiencies.
|
|
| • | Clinical progress: The molecule is under evaluation in the Phase I POLAR study, testing RP‑3467 as both monotherapy and in combination with olaparib across ovarian, breast, prostate, and pancreatic cancers.
|
|
| • | Pipeline integration: The acquisition complements Gilead’s emerging DDR portfolio and strengthens synergies with its existing PARP inhibitor collaborations.
|
|
| • | Strategic oncology focus: The transaction reinforces Gilead’s long‑term ambition to expand in precision oncology and synthetic lethality‑based treatment paradigms.
|
|
| |
A Strategic Step Forward
|
| |
For Gilead Sciences, the acquisition marks another step toward building a differentiated oncology portfolio centered on mechanism‑driven, biomarker‑guided therapies. For Repare Therapeutics, it reflects the growing validation of its synthetic lethality discovery platform and provides non‑dilutive capital to advance its broader pipeline. Together, the partnership highlights increasing industry confidence in Polθ inhibition as a promising frontier in targeted cancer treatment.
|
| |
BioMarin Expands Rare Disease Leadership with $4.8B Acquisition of Amicus
|
| |
Strengthening Portfolio Across Fabry, Pompe, and Kidney Disorders
|
| |
BioMarin has entered into a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in an all‑cash transaction, representing a total equity value of approximately $4.8 billion. The acquisition will significantly expand BioMarin’s commercial rare disease portfolio, adding Galafold (migalastat) for Fabry disease and Pombiliti (cipaglucosidase alfa‑atga) plus Opfolda (miglustat) for Pompe disease. The transaction is expected to close in Q2 2026, subject to customary regulatory approvals.
|
| |
Why This Acquisition Matters
|
| |
| • | High‑value transaction: The $4.8 billion all‑cash deal strengthens BioMarin’s position as a global rare disease leader with a diversified portfolio of commercial and late‑stage assets.
|
|
| • | Complementary portfolio: The addition of Galafold and Pombiliti + Opfolda consolidates BioMarin’s presence in rare metabolic diseases, expanding its footprint in enzyme replacement and oral chaperone therapies.
|
|
| • | Pipeline expansion: Amicus contributes U.S. rights to DMX‑200, a Phase III small‑molecule for focal segmental glomerulosclerosis (FSGS), broadening BioMarin’s reach into rare kidney disorders.
|
|
| • | Commercial synergies: The acquisition unites BioMarin’s global infrastructure with Amicus’s well‑established commercial channels, enabling accelerated growth and operational efficiencies.
|
|
| • | Strategic growth focus: The combination enhances BioMarin’s revenue base, while fortifying its long‑term pipeline across genetically defined and metabolic diseases.
|
|
| |
A Strategic Step Forward
|
| |
For BioMarin, the acquisition marks a transformative leap toward sustained leadership in rare and ultra‑rare diseases, integrating differentiated assets with durable market potential. For Amicus, the deal ensures global scale and continued investment in its approved and late‑stage programs. Together, the companies are poised to drive next‑generation therapies for Fabry, Pompe, and FSGS, underscoring a shared commitment to improving outcomes for patients with complex, underserved conditions.
|
| |
Sanofi Bolsters Vaccine Leadership with $2.2B Acquisition of Dynavax
|
| |
Combining a Proven Hepatitis B Vaccine with Next‑Generation Pipeline Candidates
|
| |
Sanofi has announced a definitive agreement to acquire Dynavax Technologies for $15.50 per share in cash, representing a total equity value of approximately $2.2 billion. The acquisition adds Dynavax’s commercialized and innovative vaccine portfolio, including Heplisav‑B, the adult hepatitis B vaccine, and Z‑1018, a next‑generation shingles vaccine candidate, as well as multiple early‑stage programs. The transaction is expected to close in Q1 2026, following customary conditions and a successful tender process.
|
| |
Why This Acquisition Matters
|
| |
| • | Transformative portfolio addition: Dynavax brings Heplisav‑B, a differentiated two‑dose, one‑month adult HBV vaccine that demonstrates faster and stronger seroprotection than traditional three‑dose, six‑month regimens.
|
|
| • | High‑value transaction: The deal, valued at $2.2 billion, underscores Sanofi’s continued investment in preventive healthcare and long‑term vaccine innovation.
|
|
| • | Pipeline enhancement: Dynavax’s Z‑1018, a Phase I/II shingles vaccine candidate, expands Sanofi’s next‑generation vaccine pipeline addressing infectious and age‑related diseases.
|
|
| • | Streamlined integration: Following a tender offer, a Sanofi subsidiary will merge with Dynavax, incorporating Dynavax’s advanced adjuvant and manufacturing platforms into Sanofi’s global network.
|
|
| • | Strategic vaccine expansion: The acquisition complements Sanofi’s leadership in adult and pediatric immunization, providing both commercial revenue and pipeline diversification.
|
|
| |
A Strategic Step Forward
|
| |
For Sanofi, the acquisition marks a pivotal advance in its mission to lead in vaccine innovation, pairing a marketed asset with a robust R&D pipeline. The addition of Heplisav‑B provides immediate commercial momentum, while Z‑1018 offers long‑term potential in a growing shingles prevention market. For Dynavax, the deal provides global reach and development acceleration under Sanofi’s established vaccine ecosystem. Together, the companies reinforce a shared commitment to expanding access to life‑saving immunizations and shaping the future of preventive health worldwide.
|
| |
|
| |
| | Pipeline Momentum: Where Clinical Data Drives Strategy
|
|
|
|
|
| |
Phase III DESTINY‑Endometrial02 trial
|
| |
|
| |
HER2-Targeted Solid Tumors
|
| |
Daiichi Sankyo Advances Enhertu into Phase III Endometrial Cancer Trial
|
| |
Daiichi Sankyo has dosed the first patient in the Phase III DESTINY‑Endometrial02 trial evaluating Enhertu (trastuzumab deruxtecan), with or without radiotherapy, in patients with HER2‑expressing endometrial cancer. The global study is being conducted in collaboration with The GOG Foundation and ENGOT, with GINECO as the lead ENGOT group. Enhertu, discovered by Daiichi Sankyo and jointly developed and commercialized with AstraZeneca, continues to expand its clinical footprint as a leading HER2‑directed antibody‑drug conjugate (ADC).
|
| |
Key Study Details
|
| |
| • | Trial design: A randomized, open‑label Phase III study enrolling approximately 710 treatment‑naïve patients with HER2‑expressing endometrial cancer (IHC 3+ or 2+).
|
|
| • | Treatment arms: Enhertu (5.4 mg/kg) ± radiotherapy compared with standard carboplatin + paclitaxel chemotherapy ± radiotherapy.
|
|
| • | Collaborative network: Conducted globally in partnership with The GOG Foundation and ENGOT, leveraging leading cooperative oncology groups to ensure diverse patient representation.
|
|
| • | Clinical significance: The trial aims to evaluate efficacy and safety outcomes, positioning Enhertu as a potential first‑line standard for HER2‑positive endometrial cancer.
|
|
| |
Global Development Context
|
| |
Enhertu has shown transformative clinical impact across breast, gastric, lung, and colorectal cancers and is now approved in more than 85 countries. The initiation of DESTINY‑Endometrial02 extends its evaluation into a new tumor type, reinforcing its potential as a pan‑tumor HER2 therapy.
|
| |
Why This Matters
|
| |
The launch of this Phase III trial highlights Daiichi Sankyo’s and AstraZeneca’s commitment to advancing precision oncology and expanding HER2 targeting beyond traditional indications. By investigating Enhertu in earlier lines and new cancer types, the partners aim to broaden access to high‑impact targeted therapies and drive further innovation in HER2‑directed oncology.
|
| |
Endocrine Therapies for Pediatric Patients
|
| |
Foresee Pharmaceuticals’ Phase III FP‑001 Demonstrates Robust Efficacy in Central Precocious Puberty
|
| |
Foresee Pharmaceuticals announced positive Phase III results from the CASPPIAN trial evaluating FP‑001 (leuprolide mesylate 42 mg)—a six‑month, sustained‑release GnRH agonist—in children with central precocious puberty (CPP). The trial successfully met its primary endpoint, underscoring FP‑001’s strong efficacy and potential to improve convenience for pediatric patients requiring hormonal suppression therapy.
|
| |
Key Outcome
|
| |
| • | At Week 24, 94% of patients achieved serum LH suppression to <4 mIU/mL at 60 minutes after a GnRHa stimulation test, exceeding the success benchmark of ≥80% and achieving statistical significance (P = 0.0005).
|
|
| • | FP‑001 was well tolerated, showing a safety profile consistent with established GnRH agonists, with no new safety concerns reported.
|
|
| • | The study results support the formulation’s six‑month dosing interval, aligning with Foresee’s sustained‑release technology aimed at reducing injection burden in chronic endocrine disorders.
|
|
| |
Regulatory Path Ahead
|
| |
Based on the CASPPIAN data, Foresee Pharmaceuticals plans to initiate global regulatory engagements, targeting an NDA submission by mid‑2026. Discussions with U.S., European, and Asian regulatory bodies are expected to shape next steps for global approval.
|
| |
Why This Matters
|
| |
The study reinforces FP‑001’s potential as a long‑acting treatment alternative that sustains robust hormonal control while significantly reducing injection frequency for children with CPP. By combining durable efficacy with patient‑centered convenience, Foresee Pharmaceuticals aims to enhance quality of life and treatment adherence in a challenging pediatric condition.
|
| |
|
| |
| | Regulatory Catalysts: Global Approvals Shaping Patient Care
|
|
|
|
|
| |
Regulatory Highlights: Major Global Approvals Across Therapeutic Areas
|
| |
|
| |
Regulators worldwide delivered a series of high-impact approvals and regulatory milestones, spanning rare diseases, oncology, cardiology, pulmonology, immunology, and metabolic disorders:
|
| |
| • | Boehringer Ingelheim secured U.S. FDA approval for Jascayd (nerandomilast) to treat progressive pulmonary fibrosis, expanding options in fibrotic lung disease.
|
|
| • | Cytokinetics reported U.S. FDA approval of Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM).
|
|
| • | Johnson & Johnson’s Tremfya (guselkumab) received European Commission approval for pediatric plaque psoriasis, extending its reach into younger patient populations.
|
|
| • | China’s NMPA approved Merck KGaA’s pimicotinib for tenosynovial giant cell tumor (TGCT).
|
|
| • | Incyte’s Minjuvi (tafasitamab) combination gained MHLW approval in Japan for relapsed/refractory follicular lymphoma.
|
|
| • | Roche received U.S. FDA approval for Lunsumio VELO, enabling subcutaneous administration in relapsed/refractory follicular lymphoma.
|
|
| • | Novo Nordisk reported U.S. FDA approval of oral Wegovy for weight management, marking a notable advance in metabolic care.
|
|
| • | Sanofi’s Wayrilz (rilzabrutinib) secured EC approval for immune thrombocytopenia.
|
|
| • | SN BioScience received U.S. FDA Orphan Drug Designation for SNB-101 in gastric cancer.
|
|
| • | Agios announced U.S. FDA approval of Aqvesme for anemia in alpha- or beta-thalassemia.
|
|
| • | Mabwell obtained U.S. FDA IND clearance to initiate a Phase IIa trial of 9MW1911 in COPD.
|
|
| • | Sanofi and Regeneron’s Dupixent (dupilumab) received MHLW approval for children with bronchial asthma in Japan.
|
|
| • | Omeros secured FDA approval for Yartemlea (narsoplimab-wuug) to treat TA-TMA.
|
|
| • | Innovent’s Tabosun (ipilimumab N01) received NMPA approval for MSI-H/dMMR resectable colon cancer.
|
|
| |
|
| |
|
| |
| | MedTech Regulatory Catalysts: Advancing Cardiovascular and Vision Care
|
|
|
|
|
| |
MedTech Regulatory Highlights: Advancing Cardiovascular and Vision Care
|
| |
|
| |
Regulatory progress in MedTech continues to reshape patient care, with new approvals accelerating the adoption of advanced cardiovascular and vision technologies across global healthcare systems.
|
| |
| • | Edwards Lifesciences received U.S. FDA approval for its SAPIEN M3 Transcatheter Mitral Valve Replacement (TMVR) System for the treatment of mitral regurgitation, marking a significant advancement in minimally invasive structural heart therapies.
|
|
| • | Bruno Vision Care announced U.S. FDA clearance for Deseyne, a novel solution for presbyopia, expanding non-invasive options for age-related vision correction.
|
|
| |
|
| |
| | Alvotech Rolls Out Simponi Biosimilar Gobivaz in Europe
|
|
|
|
|
| |
Alvotech Launches Simponi Biosimilar Gobivaz Across Europe
|
| |
|
| |
Alvotech has announced the launch of Gobivaz (AVT05), a biosimilar to Simponi (golimumab), for the treatment of multiple chronic inflammatory diseases, with commercialization led by Advanz Pharma.
|
| |
In the UK, the launch is backed by a successful NHS England tender award, while rollout across EEA markets will progress in line with country-specific pricing, reimbursement, and market access pathways. Gobivaz is offered in identical dosage forms and presentations to the reference product and is manufactured at Alvotech’s Iceland facility, supporting reliable supply.
|
| |
|
| |
| | Warm Wishes for a Healthy, Bright Holiday Season
|
|
|
|
|
| |
As the year comes to a close, we extend our warmest holiday wishes to our readers, partners, and the global healthcare community. Thank you for being part of the PharmaShots journey, here’s to a joyful holiday season and a healthier, brighter year ahead.
|
| |
|
| |
|
| |
| | That’s a Wrap for This Week
We will see you next week
|
|
|
|
|
| |
Quiet Week, Loud Signals: The Moves Reshaping Life Sciences
|
| |
This week’s PharmaShots Weekly captures a holiday period that was anything but quiet for life sciences.
|
| |
Big-ticket deals set the tone, led by Shionogi’s $2.5B Radicava buyout, AstraZeneca’s $2B KRAS alliance with Jacobio, Ipsen’s $1.06B oncology licensing deal, and Windward Bio’s $700M dual-target asthma bet.
|
| |
Mega-cap biopharma stayed active, with Pfizer, Roche, Novartis, Merck, J&J, Sanofi, AstraZeneca, and GSK advancing pipelines, securing approvals, and sharpening 2026 strategies.
|
| |
Clinical momentum continued, as Daiichi Sankyo advanced Enhertu into Phase III endometrial cancer and Foresee delivered positive Phase III data in pediatric endocrine care.
|
| |
Regulators delivered globally, with approvals across oncology, cardiology, pulmonology, metabolic disease, rare disorders, and MedTech—alongside Alvotech’s European biosimilar launch.
|
| |
Bottom line: Even during the holidays, the industry kept moving—deals closed, trials advanced, and 2026 positioning took shape. PharmaShots tracked the signals that matter.
|
| |
Stay curious. Stay informed. Stay ahead—with PharmaShots Weekly.
|
| |
We return next Monday at 8 AM EST with the signals that matter most—pipeline inflections, competitive shifts, regulatory milestones, and strategic moves—distilled in minutes, not hours.
|
| |
If this edition sparked a new perspective or sharpened your decision-making, make it a habit. Subscribe to PharmaShots Weekly for a concise, credible, leader-ready intelligence brief—delivered with precision, every week.
|
| |
Know someone in R&D, competitive intelligence, strategy, or business development who values clarity over clutter? Forward this issue. If a key insight resonated, share it on LinkedIn and tag us—we’re glad to amplify smart takes.
|
| |
The industry moves fast. Your intelligence should move faster.
Let PharmaShots keep you one step ahead—every week.
|
| |
|
| |
| | Questions?
Reach out to us [email protected] for any comments, questions, partnership and media inquiry.
|
|
|
|
|
| |
|
0 comments